Merck & Co. Inc. gained an anticipated FDA approval Monday for Grastek, its immunotherapy tablet for grass pollen-induced allergies, adding direct competition for Greer Laboratories Inc.'s recently approved Oralair in a race to expand the reach of disease-modifying allergy treatments.